The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 2, 2008, Pages 196-204

  Green, Hannah ^a   Tilston, Peter ^b   Fearnhill, Esther ^a   Pillay, Deenan ^c,d   Dunn, David T ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Definitions; Genotypic; HIV; Mutations; Transmitted resistance

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TIPRANAVIR; VIRUS RNA;

ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MUTATION; PRIORITY JOURNAL; UNITED KINGDOM; COMPARATIVE STUDY; DISEASE TRANSMISSION; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; VIROLOGY;

DRUG RESISTANCE, VIRAL; GENOTYPE; GREAT BRITAIN; HIV; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RNA, VIRAL;

EID: 55249124972     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318185725f     Document Type: Article

References (27)

1. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004;9:695-702.
2. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22-32.
3. Shafer RW, Rhee S, Pillay D, et al. HIV-1. protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21:215-223.
4. HIV Drug Resistance in the United Kingdom: Data to the End of 2005. Health Protection Report. Health Protection Agency: London, UK. Vol 1. No. 31; August 3, 2007.
5. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, and UK Register of Seroconverters. Evidence of a decline in transmitted HIV-1 drug resistance in the UK. AIDS. 2007;21:1035-1039.
6. UK Group on HIV Transmitted Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;331:1368-1371.
7. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ. 2005;330:695-698.
8. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006;14:125-130.
9. HIValg Program: Comparison of Genotypic Resistance Algorithms. Available at: http://hivdb.stanford.edu/pages/algs/HiVdb.html. Version 4.3.0; July 2007. Accessed August 21, 2008.
10. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283:2417-2426.
11. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Update of drug resistance mutations in HIV-1. Top HIV Med. 2001;9:21-27.
12. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIVMed. 2002;10:21-25.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:215-221.
14. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1:2004. Top HIV Med. 2004;12:119-124.
15. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HTV-1:Fall 2005. Top HIV Med. 2005;13:125-131.
16. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41:1316-1323.
17. Booth CL, Geretti AM, Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59:1047-1056.
18. Masquelier B, Bhaskaran K, Pillay D, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms. J Acquir Immune Defic Syndr. 2005;40:505-511.
19. Wensing AMJ, van de Vijver DA, Andarano G, et al. Prevalence of drugresistant .HIV-I variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966.
20. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1. A decade of experience. J Acquir Immune Defic Syndr. 2006;41:439-446.
21. Weinstock. HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1.-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-2180.
22. Hurt C, McCoy S, Kerkau M, et al. Frequency of transmitted drug resistance among acute and recently HIV-infected patients in North Carolina is similar to reports from more urbanized areas. Antivir Ther. 2007;12:S55.
23. Liu L, May S, Richman D, et al. Comparison of resistance algorithms to determine prevalence of transmitted drug resistance. Antivir Ther. 2007; 12:S58.
24. Ross LL, Williams V, Wine B, et al. Changes in the regional prevalence of HIV-1 drug resistance-associated mutations and in the prevalence on nonclade B subtypes in antiretroviral therapy-naive HIV-infected patients in the United States from. 2000-2006. Antivir Ther. 2007;12:S54.
25. Dunn DT, Green H, Matthias R, et al. Prevalence of reduced drug susceptibility in treatment-naive patients in the UK. Antivir Ther. 2004;9: S107.
26. Kozal MJ, Huppler Hullsiek K, Leduc R, et al. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatmentnaive and treatment-experienced patients. Antivir Ther. 2006; 11:457-463.
27. Milhailidis C, Dunn D, Pillay D, et al. Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy. AIDS. 2008;22:427-432.